Firebrick Pharma Limited (FRE.AX)
AUD 0.07
(-2.86%)
AUD 0.07
(-2.86%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -1.08 Million AUD | 84.08% |
| 2023 | -6.81 Million AUD | -81.08% |
| 2022 | -3.5 Million AUD | -32.29% |
| 2021 | -2.43 Million AUD | -42.52% |
| 2020 | -1.49 Million AUD | -71.17% |
| 2019 | -1.17 Million AUD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 FY | - AUD | 42.8% |
| 2024 Q4 | -108.14 Thousand AUD | 0.0% |
| 2024 Q1 | -434.2 Thousand AUD | 88.15% |
| 2024 Q2 | -907.07 Thousand AUD | -106.08% |
| 2024 Q3 | -108.14 Thousand AUD | 87.91% |
| 2023 Q1 | -1.55 Million AUD | 30.87% |
| 2023 FY | - AUD | -81.08% |
| 2023 Q4 | -3.68 Million AUD | -102.94% |
| 2023 Q3 | -1.81 Million AUD | 42.21% |
| 2023 Q2 | -3.14 Million AUD | -102.37% |
| 2022 Q4 | -2.24 Million AUD | -102.72% |
| 2022 FY | - AUD | -32.29% |
| 2022 Q3 | -1.1 Million AUD | 13.69% |
| 2022 Q2 | -1.28 Million AUD | -100.0% |
| 2022 Q1 | -642.36 Thousand AUD | 13.68% |
| 2021 Q1 | -475.36 Thousand AUD | 0.0% |
| 2021 FY | - AUD | -42.52% |
| 2021 Q4 | -744.14 Thousand AUD | -0.01% |
| 2021 Q3 | -744.09 Thousand AUD | 21.73% |
| 2021 Q2 | -950.72 Thousand AUD | -100.0% |
| 2020 FY | - AUD | -71.17% |
| 2019 FY | - AUD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Mayne Pharma Group Limited | -116.92 Million AUD | 99.072% |